Stefan Rehnmark
Chief Tech/Sci/R&D Officer chez GABATHER AB
Profil
Stefan Rehnmark is the founder of Axcentua Pharmaceuticals AB, which was founded in 2007.
He held the title of Chief Executive & Scientific Officer at the company.
Dr. Rehnmark is also the founder of Noviga Research AB.
He is currently the Chief Scientific Officer at Gabather AB.
Dr. Rehnmark previously worked as an Assistant Professor at the University of Stockholm from 1994 to 2000.
He obtained a doctorate degree from the University of Stockholm.
Postes actifs de Stefan Rehnmark
| Sociétés | Poste | Début |
|---|---|---|
| GABATHER AB | Chief Tech/Sci/R&D Officer | 01/01/2018 |
Anciens postes connus de Stefan Rehnmark
| Sociétés | Poste | Fin |
|---|---|---|
| University of Stockholm | Corporate Officer/Principal | 01/01/1998 |
| Noviga Research AB | Founder | - |
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Chief Executive Officer | - |
Formation de Stefan Rehnmark
| University of Stockholm | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GABATHER AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
| Noviga Research AB |
